"Compared with discovering a great business model, it is more exciting and expectant to have a good relationship with entrepreneurs and entrepreneurs who have a great view of the landscape."

—— "Value" Zhang Lei

Recently, TIANS Group successfully won the bid for the Phase III 1PQ expansion project of BeiGene (Guangzhou) Biopharmaceutical Co., Ltd. The project mainly includes the electromechanical purification project of the QC workshop and the installation of the HVAC system of the elevated warehouse. After more than two months of serious organization and multiple exchanges, the TIANS Group technical team stood out from many bidders with a rigorous working attitude, detailed BIM space management optimization plan and professional verification document system, and finally successfully won the bid.

Work together again to shape value

The cooperation between TIANS and BeiGene this time is actually a second joint effort. As early as May and August this year, TIANS has already cooperated with BeiGene in the field of consulting design and automation, and they have undertaken BeiGene respectively. Shenzhou (Guangzhou) Biopharmaceutical Co., Ltd. Phase IV new plant design project and BeiGene (Guangzhou) Biopharmaceutical Co., Ltd. Phase III project stock solution workshop and BMS&EMS automation project of the biological island project. The winning of the bid this time also reflects BeiGene's full recognition of the professional attitude and technical capabilities of the TIANS team.

To the strong side by side to go to the stars

As the “top stream” of domestic biomedicine, BeiGene has only spent eleven years from being a local innovative company to now becoming a biotechnology company in the forefront of China and the world, and as a leader and practicer of the EPC model of medical engineering Xingzhe TIANS has also been continuously improving its design and construction capabilities in the pharmaceutical industry during these eleven years.

Since its establishment in 1998, TIANS Group has fully entered the EPC general contracting industry in 2010. During the development of the pharmaceutical industry, it has gradually formed a technology-led general contracting model and successfully ranked among the national survey and design enterprises in general contracting. The list has served more than 50 "top 100 pharmaceutical industry" corporate customers, and built more than a thousand industry-quality projects across the country. In the direction of biomedicine, in addition to cooperating with BeiGene, TIANS has also carried out extensive cooperation with many well-known biopharmaceutical companies such as Junshi Bio, Shanghai Pharmaceutical Kangsino, Si Microbiology, WuXi Biotech and other well-known biomedical companies.

"Being an affordable anticancer drug for Chinese people" is the ultimate ideal of domestic pharmaceutical companies including BeiGene. To provide more complete and accurate plant facilities for the majority of pharmaceutical companies, and to exceed customer expectations is the lasting goal and belief of TIANS Group rooted in the pharmaceutical industry. This time, TIANS once again joined hands with BeiGene, and I believe it will create another outstanding case of biomedical projects for the industry.

About BeiGene

BeiGene is a global, commercial-stage, R&D-based biotechnology company, focusing on the research and development of molecular targeting and immuno-oncology therapies.

It was founded in Beijing in 2010 and landed on Nasdaq in February 2016, becoming the first Chinese innovative biopharmaceutical company to go public in the United States. It was listed in Hong Kong in August 2018. On November 16, 2021, the China Securities Regulatory Commission also issued an announcement stating that it agreed to register BeiGene’s initial public offering on the Science and Technology Innovation Board. This move marked the official countdown to BeiGene’s landing in the domestic A-share market, and it also meant the world’s first Biotechnology companies listed on the Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange will soon be born. At the same time, BeiGene has reached strategic cooperation with a number of multinational pharmaceutical giants and biotechnology innovation companies, setting precedents in the industry repeatedly.